Cowen Initiates Outperform On Keryx Biopharmaceuticals, Sees 64% Upside
In a research report sent to investors today, Cowen analyst Boris Peaker initiated coverage on Keryx Biopharmaceuticals (NASDAQ:KERX) with an Outperform rating and a $25 price target, which represents a potential upside of 64% from where the stock is currently trading.
In his initiation report, Peaker noted, “Based on consultant feedback we anticipate Auryxia to be successful in the US market and we estimate US peak sales of ~$1B in 2024. In our view, economic incentive has a significant impact on dialysis practice in the US, and Auryxia’s ESA and iron sparing properties will drive its adoption.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Boris Peaker has a total average return of 30.3% and a 63.4% success rate. Peaker has a 177.1% average return when recommending KERX, and is ranked #91 out of 3395 analysts.